Department of Urology, The People's Hospital of Yubei District of Chongqing, Chongqing, China.
Department of Urology, The General Hospital of Chongqing Steel Company, Chongqing, China.
World J Urol. 2024 Jun 7;42(1):370. doi: 10.1007/s00345-024-05084-0.
The objective was to evaluate the efficacy of transcutaneous electrical nerve stimulation (TENS) combined with mirabegron therapy compared with mirabegron monotherapy in the treatment of female patients with overactive bladder (OAB).
In this randomized controlled study, 100 female outpatients with OAB were screened. Among these patients, 86 who met the inclusion criteria were randomly divided into the TENS combined with mirabegron treatment group and mirabegron monotherapy treatment group, with 43 patients in each group. The voiding diary, Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire Symptom Bother Score (OAB-q SBS), total health-related quality of life (OAB-q HRQoL), and treatment satisfaction-visual analog scale (TS-VAS) score before and after treatment were recorded to evaluate the efficacy of OAB treatment. Seventy-nine of the 86 patients (40 in the TENS plus mirabegron group and 39 in the mirabegron monotherapy group) completed 12 weeks of treatment.
TENS combined with mirabegron therapy was superior to mirabegron monotherapy in improving the primary endpoints, including the daily number of micturition episodes and the daily MVV/micturition and secondary endpoints, including the daily number of urgency episodes, the OABSS, the OAB-q SBS, the HRQoL score and TS-VAS score. There were no statistically significant differences in urgency urinary incontinence and nocturia between the groups. Some minor adverse effects were observed, including muscle pain, local paresthesia and constipation.
The combination of TENS and mirabegron was more effective than mirabegron alone in the treatment of female patients with OAB.
ChiCTR2400080528 (31.01.2024, retrospectively registered).
评估经皮神经电刺激(TENS)联合米拉贝隆治疗与米拉贝隆单药治疗在治疗女性膀胱过度活动症(OAB)患者中的疗效。
在这项随机对照研究中,筛选了 100 名女性 OAB 门诊患者。在这些患者中,符合纳入标准的 86 名患者被随机分为 TENS 联合米拉贝隆治疗组和米拉贝隆单药治疗组,每组 43 例。记录治疗前后排尿日记、膀胱过度活动症症状评分(OABSS)、膀胱过度活动症问卷症状困扰评分(OAB-q SBS)、总健康相关生活质量(OAB-q HRQoL)和治疗满意度视觉模拟评分(TS-VAS),以评估 OAB 治疗的疗效。86 例患者中的 79 例(TENS 联合米拉贝隆组 40 例,米拉贝隆单药治疗组 39 例)完成了 12 周的治疗。
TENS 联合米拉贝隆治疗在改善主要终点(每日排尿次数和每日最大尿流率/排尿次数)和次要终点(每日尿急次数、OABSS、OAB-q SBS、生活质量评分和 TS-VAS 评分)方面均优于米拉贝隆单药治疗。两组间急迫性尿失禁和夜间多尿无统计学差异。观察到一些轻微的不良反应,包括肌肉疼痛、局部感觉异常和便秘。
与米拉贝隆单药治疗相比,TENS 联合米拉贝隆治疗女性 OAB 患者的疗效更优。
ChiCTR2400080528(31.01.2024, retrospectively registered)。